Literature DB >> 28636701

The Metabolodiuretic Promise of Sodium-Dependent Glucose Cotransporter 2 Inhibition: The Search for the Sweet Spot in Heart Failure.

Subodh Verma1, John J V McMurray2, David Z I Cherney3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28636701     DOI： 10.1001/jamacardio.2017.1891

Source DB:  PubMed          Journal:  JAMA Cardiol            Impact factor:   14.676


× No keyword cloud information.
  39 in total

Review 1.  SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review.

Authors:  Subodh Verma; John J V McMurray
Journal:  Diabetologia       Date:  2018-08-22       Impact factor: 10.122

Review 2.  SGLT2 inhibitors: the future for treatment of type 2 diabetes mellitus and other chronic diseases.

Authors:  Christoph Wanner; Nikolaus Marx
Journal:  Diabetologia       Date:  2018-08-22       Impact factor: 10.122

3.  Empagliflozin reduces albuminuria-a promise for better cardiorenal protection from the EMPA-REG OUTCOME trial.

Authors:  Rikke Borg; Frederik Persson
Journal:  Ann Transl Med       Date:  2017-12

Review 4.  Preventing Diabetes and Atherosclerosis in the Cardiometabolic Syndrome.

Authors:  Muhammad Imtiaz Ahmad; Michael D Shapiro
Journal:  Curr Atheroscler Rep       Date:  2021-03-09       Impact factor: 5.113

5.  What does sodium-glucose co-transporter 1 inhibition add: Prospects for dual inhibition.

Authors:  Jessica A Dominguez Rieg; Timo Rieg
Journal:  Diabetes Obes Metab       Date:  2019-04       Impact factor: 6.577

Review 6.  The New Biology of Diabetic Kidney Disease-Mechanisms and Therapeutic Implications.

Authors:  Yuliya Lytvyn; Petter Bjornstad; Daniel H van Raalte; Hiddo L Heerspink; David Z I Cherney
Journal:  Endocr Rev       Date:  2020-04-01       Impact factor: 19.871

Review 7.  SGLT2 Inhibition in Type 1 Diabetes with Diabetic Kidney Disease: Potential Cardiorenal Benefits Can Outweigh Preventable Risk of Diabetic Ketoacidosis.

Authors:  Hongyan Liu; Vikas S Sridhar; Bruce A Perkins; Julio Rosenstock; David Z I Cherney
Journal:  Curr Diab Rep       Date:  2022-05-28       Impact factor: 4.810

Review 8.  Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes-cardiovascular and renal benefits in patients with chronic kidney disease.

Authors:  Tamara Y Milder; Sophie L Stocker; Dorit Samocha-Bonet; Richard O Day; Jerry R Greenfield
Journal:  Eur J Clin Pharmacol       Date:  2019-08-03       Impact factor: 2.953

Review 9.  [Update on heart failure].

Authors:  J Wintrich; I Kindermann; M Böhm
Journal:  Herz       Date:  2018-06-05       Impact factor: 1.443

Review 10.  Further insights into cardiovascular outcomes in diabetic and non-diabetic states: inhibition of sodium-glucose co-transports.

Authors:  Zhao Li
Journal:  Cardiovasc Endocrinol Metab       Date:  2019-11-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.